·seekingalpha.comMed
Nyxoah reports Q3 results (NYXH:NASDAQ)
Nyxoah reported Q3 results, with an EPS loss of €0.18 and revenue of €9.2M, up 365% year-over-year. The company also announced a new CEO and interim CFO.
StockNASDAQ · US · USDHealthcare · Medical Instruments & Supplies
$NYXH
Nyxoah SA
Nyxoah is a medical technology company that develops and commercializes treatments for obstructive sleep apnea. Its lead product, the Genio system, is a hypoglossal neurostimulation therapy for adults with moderate to severe sleep apnea who did not tolerate, failed or refused positive airway pressure therapy. Implanted through a single incision, the system uses an external power source and delivers bilateral stimulation. The Genio 2.1 system includes a smartphone application and an upgraded external activation chip. Nyxoah earns money from sales of the Genio system. It began selling the system in Europe in July 2020 and in the United States in September 2025, and also markets it in other countries, including Germany, Switzerland, Spain, Finland, Austria, England, Abu Dhabi and the Netherlands. The company is headquartered in Mont-Saint-Guibert, Belgium.
Price · $NYXHvia TradingView
AI sentiment · 7d4 articles
- Bullish
- 1
- Neutral
- 1
- Bearish
- 2
Insider · 30dAll trades →
No SEC Form 4 filings for $NYXH in the last 30 days.
See all $NYXH insider activity →Top stories · $NYXHMore →
·finance.yahoo.com
Nyxoah SA (NYXH) Q3 2026 Earnings Call Highlights
Nyxoah SA (NYXH) reported Q3 2026 revenue of EUR9.2M, up 365% YoY. CEO Liam Kelly highlighted U.S. market opportunities, adjusted FY 2026 revenue guidance to EUR33M-EUR35M, and progress in CCC PMA supplement submission. The company trained 80 new surgeons and activated 53 new accounts. CMS reimbursement for Genio procedure increased by 11-13%. Cash position was EUR77.1M as of Q3 2026.
·SEC EDGAR 6-K
Nyxoah SA (NYXH): Financial results for Q3 2026
Nyxoah SA (NYXH) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Third Quarter 2026 Financial and Operating Results Global net revenue was €9.2 million driven by 29% sequential U.S. net revenue growth PMA supplement submitted to the FDA to expand Genio’s U.S. indication to include Complete Conc
NYXH sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning NYXH (Nyxoah SA). Coverage has skewed bearish: 1 bullish, 1 neutral, and 2 bearish.
Recent NYXH coverage spans earnings, financial news and technology.
What's driving NYXH
Earnings miss on profit but strong revenue growth.
Earnings beat and guidance update provide fresh data for NYXH.
The earnings beat and issued guidance may provide modest upside support.
Cantor Fitzgerald kept its Overweight rating on Nyxoah (NYXH) with a $3 price target, suggesting a 282% upside from the Oct 26 close. The firm cites positive leading indicators, including 80 new trained surgeons and 53 activated accounts in Q3, and the appointment of Liam Kelly as CEO.
Positive clinical-to-regulatory update that could broaden Genio’s label and improve commercial addressable market if FDA accepts/approves the supplement.
AlphAI scores every news story that mentions NYXH with an AI model for sentiment and relevance, and aggregates insider trades from Nyxoah SA's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $NYXH
Score
Nyxoah reports Q3 results (NYXH:NASDAQ)
Nyxoah reported Q3 results, with an EPS loss of €0.18 and revenue of €9.2M, up 365% year-over-year. The company also announced a new CEO and interim CFO.
Nyxoah SA (NYXH) Q3 2026 Earnings Call Highlights
Nyxoah SA (NYXH) reported Q3 2026 revenue of EUR9.2M, up 365% YoY. CEO Liam Kelly highlighted U.S. market opportunities, adjusted FY 2026 revenue guidance to EUR33M-EUR35M, and progress in CCC PMA supplement submission. The company trained 80 new surgeons and activated 53 new accounts. CMS reimbursement for Genio procedure increased by 11-13%. Cash position was EUR77.1M as of Q3 2026.
Nyxoah SA (NYXH): Financial results for Q3 2026
Nyxoah SA (NYXH) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Third Quarter 2026 Financial and Operating Results Global net revenue was €9.2 million driven by 29% sequential U.S. net revenue growth PMA supplement submitted to the FDA to expand Genio’s U.S. indication to include Complete Conc
Cantor Fitzgerald maintains Overweight rating on Nyxoah, $3 price target
Cantor Fitzgerald kept its Overweight rating on Nyxoah (NYXH) with a $3 price target, suggesting a 282% upside from the Oct 26 close. The firm cites positive leading indicators, including 80 new trained surgeons and 53 activated accounts in Q3, and the appointment of Liam Kelly as CEO.
Nyxoah SA (NYXH) Reports 74.3% AHI Median Reduction; Files FDA PMA Supplement
Nyxoah SA reported 12-month ACCCESS data showing a 74.3% median AHI reduction with Genio in CCC OSA patients. The company filed a PMA supplement with the FDA to expand Genio’s indication to CCC patients, with no serious adverse events reported. According to Nyxoah, a positive FDA decision could be a significant commercial catalyst.
Nyxoah shares fall after CFO departure announcement
Nyxoah SA (NYXH) shares dropped 2% after-hours after CFO John Landry announced his departure in 2026. Loïc Moreau will serve as interim CFO. The company reaffirmed its 2026 guidance: €36M-€40M revenue, 60%-62% gross margin, and €99M-€102M operating expenses.
Nyxoah stock surges as sleep apnea study hits endpoints
Nyxoah SA (NYXH) shares rose 11.9% after its ACCCESS U.S. study met primary safety and efficacy endpoints. The Genio system showed a 77.2% Apnea-Hypopnea Index responder rate and zero device-related serious adverse events. The company plans to submit a premarket approval supplement to the FDA for expanded indication.
Nyxoah's ACCCESS Trial Of Genio System Meets Primary Goals In CCC Sleep Apnea Patients; Shares Jump
Nyxoah SA (NYXH) reported positive results from its ACCCESS trial for the Genio system in treating sleep apnea with Complete Concentric Collapse (CCC). The study met primary efficacy and safety endpoints, with 77.2% AHI responder rate and 87.7% ODI responder rate. NYXH shares rose 29.14% in overnight trading.
Nyxoah S.A. Q2 Loss Widens
Nyxoah S.A. (NYXH) reported a wider Q2 GAAP loss of EUR32.96 million, or EUR0.578 per share, versus a EUR20.61 million loss and EUR0.551 per share a year earlier. Revenue increased 473.1% to EUR7.68 million from EUR1.34 million, according to the company.
Nyxoah SA (NYXH): Financial results for Q2 2026
Nyxoah SA (NYXH) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results U.S. commercial execution driving continued launch momentum resulting in 22% sequential U.S. revenue growth in Q2 2026 over Q1 2026 Mont-Saint-Guibert, Belgium –